🔬 These standards help measure empty and full AAV capsids, ensuring safer gene therapies.
🤝 Developed with multiple labs, the standards enhance consistency in AAV assessments.
📜 Mass photometry is now part of best practices for AAV product quality control, improving accuracy in capsid evaluation.
Introduction:
The recognition of mass photometry by the US Pharmacopeia (USP) marks a significant advancement in the standardization of adeno-associated virus (AAV) reference standards for gene therapy. This development is pivotal for ensuring the accurate characterization of AAVs, which are crucial for gene delivery in therapeutic applications.
- The USP has acknowledged mass photometry as an important orthogonal method for characterizing new AAV reference standards.
- The new standards enable measurement of both empty and full AAV capsids through a comprehensive multi-laboratory study.
- Proper quantification of the empty/full capsid ratio is essential for the safety and efficacy of AAV-based gene therapies.
- The collaboration among scientists led to the development of these standards, addressing the need for consistency in AAV assessments.
- Mass photometry is highlighted in the USP’s upcoming general chapter <1067>, which emphasizes the use of multiple techniques for accurate capsid analysis.
Conclusion:
The incorporation of mass photometry into AAV quality assessment protocols by the USP represents a major step towards harmonizing testing methods in gene therapy. This initiative not only provides a reliable framework for AAV characterization but also supports advancements in the manufacturing processes, underscoring the ongoing evolution in the field of gene therapy and its quality control practices.
